La bourse ferme dans 1 h 35 min
  • CAC 40

    6 648,28
    +25,69 (+0,39 %)
     
  • Euro Stoxx 50

    4 177,77
    +7,90 (+0,19 %)
     
  • Dow Jones

    34 665,82
    -85,50 (-0,25 %)
     
  • EUR/USD

    1,1758
    -0,0014 (-0,12 %)
     
  • Gold future

    1 750,10
    -6,60 (-0,38 %)
     
  • BTC-EUR

    40 281,36
    -478,18 (-1,17 %)
     
  • CMC Crypto 200

    1 203,88
    -21,65 (-1,77 %)
     
  • Pétrole WTI

    71,88
    -0,73 (-1,01 %)
     
  • DAX

    15 628,87
    -22,88 (-0,15 %)
     
  • FTSE 100

    7 031,63
    +4,15 (+0,06 %)
     
  • Nasdaq

    15 107,44
    -74,49 (-0,49 %)
     
  • S&P 500

    4 452,24
    -21,51 (-0,48 %)
     
  • Nikkei 225

    30 500,05
    +176,71 (+0,58 %)
     
  • HANG SENG

    24 920,76
    +252,91 (+1,03 %)
     
  • GBP/USD

    1,3778
    -0,0019 (-0,14 %)
     

DisperSol Technologies Promotes Chris Brough to Chief Technology Officer

·3 min de lecture

Brough to Lead the DisperSol Technology Center

GEORGETOWN, Texas, July 14, 2021--(BUSINESS WIRE)--DisperSol Technologies LLC announced today that it is promoting Chris Brough from Vice President Technology to Chief Technology Officer effective immediately.

"Chris Brough has been an integral figure in DisperSol since its founding," said Dr. Edward Rudnic, CEO of DisperSol Technologies. "Beyond being a co-inventor and innovation leader in our core KinetiSol technology, Chris has built our DisperSol Technology Center. At the DTC, we are now fully integrated in designing, building and programming our proprietary manufacturing equipment. His engineering, scientific and business acumen has been instrumental in both the company’s growth, and the technology’s evolution from a laboratory device to a commercial engine. It is with great pleasure that we recognize his many past contributions and key role in our future growth by promoting him to Chief Technology Officer."

"It is an honor becoming DisperSol’s first Chief Technology Officer," said Chris Brough. "I look forward to leveraging the new capabilities we’ve created at the DTC to continue to keep DisperSol on the cutting edge of amorphous solid dispersion drug development. DisperSol has evolved into a late clinical stage pharmaceutical company that is now gearing up for commercial manufacturing of its products. My team and I will continue our work to ensure a successful future for the company and its pipeline."

Dr. Brough is a primary developer of KinetiSol. In 1999, he started a plastics recycling company based on a novel patented process that he invented, a forerunner to KinetiSol. That company was acquired by IntegriCo Composites in 2005. As IntegriCo’s VP of Engineering and Product Development, Chris led the development and deployment of his technology at IntegriCo and into multiple plastics industry partners. In 2006, Chris met Dave Miller and the two tested the technology for a new application, creating solid amorphous dispersions of pharmaceuticals. Upon successful results, Chris redesigned the equipment for pharmaceutical GMP use and was a co-founder of DisperSol Technologies in 2007. Chris holds a BS and MS in mechanical engineering along with an MBA from Brigham Young University and has a PhD in Pharmaceutics from the University of Texas at Austin. His research focused on drug solubility enhancement and abuse deterrent formulation applications of the KinetiSol process.

About DisperSol Technologies

DisperSol is a clinical-stage drug development company focused on developing new treatments for patients utilizing its proprietary KinetiSol® technology platform. KinetiSol has proven capable of creating novel therapeutics from poorly bioavailable drugs to deliver unique clinical benefits to patients. The platform enables a drug development path forward to patients when other options fail to make a difference. DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders. Additional earlier-stage programs include, DST-0058 and DST-5407 for idiopathic pulmonary fibrosis and non-squamous non-small cell lung cancer, respectively.

For more information, visit www.dispersoltech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005768/en/

Contacts

Raj Sheel
Vice President, Business Development & Marketing
512-686-5185
raj.sheel@dispersoltech.com

Notre objectif est de créer un endroit sûr et engageant pour que les utilisateurs communiquent entre eux en fonction de leurs centres d’intérêt et de leurs passions. Afin d'améliorer l’expérience dans notre communauté, nous suspendons temporairement les commentaires d'articles